AstraZeneca Plans New API Manufacturing Facility in Ireland

AstraZeneca said it plans to establish an active pharmaceutical ingredient (API) manufacturing plant for small molecules in Ireland.

The goal of the $360 million investment is to reduce time to drug commercialization, lower costs and enable more sustainable manufacturing processes, the Anglo-Swedish drugmaker said.

The APIs will include “compounds with highly complex synthesis, requiring next-generation technologies and capabilities that can respond quickly and nimbly to rapidly changing clinical and commercial needs,” said Pam Cheng, the company’s executive vice president of global operations and IT.